Bristol Myers Squibb’s Zeposia (ozanimod) Receives CHMP’s Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis Published: 15 Oct, 2021 | Tags: Bristol Myers Squibb, Zeposia, ozanimod, […]readmore
Tags : Repotrectinib
Shots: The P-I/II TRIDENT-1 study evaluates repotrectinib in NTRK-positive TKI-naïve & pretreated advanced solid tumors. The early P-II data use an Aug 26, 2021 cutoff data The preliminary efficacy analysis […]readmore
Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The Breakthrough Designation is granted to […]readmore
Shots: The US FDA has been granted BTD for the treatment of patients with ROS1+ metastatic NSCLC who have not been treated with ROS1 TKI-naïve The designation is based on […]readmore
Shots: Turning Point to receive $25M as upfront, $151M as development, regulatory and commercial milestones along with royalties on sales of repotrectinib in Greater China. Zai Lab to get exclusive […]readmore